Eisai Co Ltd - Company Profile
Powered by 
All the data and insights you need on Eisai Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Eisai Co Ltd Strategy Report
- Understand Eisai Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Eisai Co Ltd (Eisai) carries out the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) and prescription drugs and therapeutic agents. The company operates through three product categories namely Oncology Products; Neurology Products; and Others.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company conducts research to advance medicines in the therapeutic areas of neurology and oncology. Eisai conducts its research activities through Neurology Business Group (NBG) and Oncology Business Group (OBG). These business units handle all functions from R&D through to sales and will carry out investment with focus on R&D for flagship candidates. The focus areas include dementia-related and neurological diseases and cancer. In FY2023, the company incurred R&D expenses of JPY172,999 million, which as a percentage of its revenue stood at 23.2%. Major pipeline products of the company include E2007 (perampanel) is in Phase III trials for the treatment of Lennox-Gastaut syndrome; E2006 (lemborexant) is in PhaseII trials for the treatment of Insomnia disorder; BAN2401 (lecanemab) is in PhaseIII trials for treatment of Alzheimer’s disease; E2023 (lorcaserin) is in Phase III trials for the treatment of Dravet syndrome; E7080 (lenvatinib) is in PhaseIII trials for the treatment of Esophageal carcinoma; E7389 (eribulin) is in phase II trials for the treatment of Liposomal formulation; AJM347 for the treatment of inflammatory bowel disease is in Phase I trilas; and FYU-981 (dotinurad) for the treatment of Gout is in phase III trials. Eisai operates production plants, namely, Kawashima plant in Gifu, Japan; Kashima Plant in Ibaraki, Japan; Fukushima Plant in Fukushima, Japan; Hatfield Plant in Hertfordshire, the UK; Suzhou plant in Jiangsu, China and Benxi Plant in Liaoning, China; and Vizag Plant in Andhra Pradesh, India. It also has seven laboratories, with three of them in Japan, three in the US and one in the UK.
Product Categories
Overview
Includes Lunesta for insomnia; antiepileptic agents including Banzel, Zonegran, Zebinix, and Fycompa; Methycobal for peripheral neuropathy; Lyrica for pain, Belviq, anti-obesity agent; and Aricept for Alzheimer’s disease, among others. The company is co-promoting Lyrica in collaboration with Pfizer Inc.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes Halaven, an anticancer agent; Lenvima for renal cell carcinoma; and Treakisym, an anticancer agent. Eisai markets Lenvima under the brand name: Kisplyx in Europe.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
- Americas
- Asia and Latin America
- China
- EMEA
- Japan
- OTC and Others
- OTC and Others Business
- Other Business
Overview
Manufactures and sells anticancer agents including Lenvima, Halaven; and antiepileptic agents such as Banzel and Fycompa. Also offers AcipHex, a proton pump inhibitor in the US.
Target Markets
Includes operations of North America.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells pharmaceutical products for the treatment of Alzheimer’s disease, cancer and peripheral neuropathy. Major products include Aricept for Alzheimer’s disease and Dementia with Lewy bodies (DLB) treatment; Pariet, a proton pump inhibitor; Lenvima and Halaven, anticancer agents; Fycompa, an antiepileptic agent; and Humira, a fully human anti-TNF- a monoclonal antibody.
Target Markets
Comprises operations in South Korea, Taiwan, India, ASEAN, Central and South America.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Methycobal for peripheral neuropathy treatment; Neo-Minophagen C and Glycyron tablets for liver disease and allergy; Lenvima and Halaven, anticancer agents; Pariet, a proton pump inhibitor; and Fycompa, an antiepileptic agent in China.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells anticancer and antiepileptic agents. Major products include Lenvima, Halaven, Fycompa, Zebinix, Zonegran and Inovelon. Offers Lenvima under brand name of Kisplyx in Europe.
Target Markets
-Comprises operations in Europe, the Middle East, Africa and Oceania.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells prescription drugs and OTC products for diseases and disorders including Alzheimer’s, cancer, liver disease, allergy and pain. Major products include Humira, a fully human anti-TNF-a monoclonal antibody; Lyrica for the treatment of pain; Lunesta for insomnia; Methycobal for peripheral neuropathy; Aricept for Alzheimer’s disease; Pariet, a proton pump inhibitor; Careram, an antirheumatic agent; Elental for elemental diet; and Goofice for chronic constipation..
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells OTC and other products including Chocola BB Group, Chocola BB plus, Sahne medical spray and cream in Japan.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes revenue from licenses and sale of pharmaceutical ingredients.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer